ConductScience.org, home

Paper36735694

Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: A study based on real-world clinical data.

Kim J and 3 others. PLoS One, 2023. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: A study based on real-world clinical data. Papers, record 36735694. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36735694

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: A study based on real-world clinical data.
PubMed
Journal
PLoS One
PubMed
Year
2023
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
1.1
iCite
Revised in PubMed
2023-04-06
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kim JJiwonhttps://orcid.org/0000-0002-7193-210X
2Chung CChiwook
3Cho HSHyo Sin
4Kim HCHo Cheolhttps://orcid.org/0000-0002-3154-4858

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Drug TaperingMajor topic
Idiopathic Pulmonary FibrosisMajor topic
Humans
Aged
Retrospective Studies
Anti-Inflammatory Agents, Non-Steroidal
Pyridones
Treatment Outcome
Vital Capacity

Source PubMed

Download CSV of topics

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132297284Safety and Efficacy of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis: A Nationwide Post-Marketing Surveillance Study in Korean Patients.Adv Ther2020https://conductscience.org/library/papers/32297284PubMed
224836312A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.N Engl J Med2014https://conductscience.org/library/papers/24836312PubMed
334941933Effects of low-dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): Results from a real-world study.PLoS One2021https://conductscience.org/library/papers/34941933PubMed
429212837Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.Eur Respir Rev2017https://conductscience.org/library/papers/29212837PubMed
525115833Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases.Respiration2014https://conductscience.org/library/papers/25115833PubMed
630470213Pirfenidone improves survival in IPF: results from a real-life study.BMC Pulm Med2018https://conductscience.org/library/papers/30470213PubMed
719420141Adverse drug reactions in elderly: challenges in identification and improving preventative strategies.Age Ageing2009https://conductscience.org/library/papers/19420141PubMed
833277557Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital.Sci Rep2020https://conductscience.org/library/papers/33277557PubMed
99713446Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts.Thorax1998https://conductscience.org/library/papers/9713446PubMed
1021571362Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.Lancet2011https://conductscience.org/library/papers/21571362PubMed
1119996196Pirfenidone in idiopathic pulmonary fibrosis.Eur Respir J2010https://conductscience.org/library/papers/19996196PubMed
1224639005Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events.Adv Ther2014https://conductscience.org/library/papers/24639005PubMed
1330665416Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry.Respir Res2019https://conductscience.org/library/papers/30665416PubMed
1423056564Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials.PLoS One2012https://conductscience.org/library/papers/23056564PubMed
1527876247Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.Lancet Respir Med2017https://conductscience.org/library/papers/27876247PubMed
1628843616Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.Pulm Pharmacol Ther2017https://conductscience.org/library/papers/28843616PubMed
1725712077Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.Eur Heart J Cardiovasc Imaging2015https://conductscience.org/library/papers/25712077PubMed
1820935110Clinical course and prediction of survival in idiopathic pulmonary fibrosis.Am J Respir Crit Care Med2011https://conductscience.org/library/papers/20935110PubMed
1931999801Real-world experiences: Efficacy and tolerability of pirfenidone in clinical practice.PLoS One2020https://conductscience.org/library/papers/31999801PubMed
2026344613All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis.Respir Investig2015https://conductscience.org/library/papers/26344613PubMed

See all 28 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
41995999Efficacy and tolerability of generic pirfenidone after switch from Esbriet® in idiopathic pulmonary fibrosis: a real-world observational study.Intern Emerg Med2026https://conductscience.org/library/papers/41995999PubMed
40356972
Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases.
Front Pharmacol2025https://conductscience.org/library/papers/40356972PubMed
39512192Real-world therapeutic performance of pirfenidone for connective tissue disease-associated interstitial lung diseases.Ther Adv Respir Dis2024https://conductscience.org/library/papers/39512192PubMed
38963453Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.Eur J Clin Pharmacol2024https://conductscience.org/library/papers/38963453PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
GPT2875PubTator's text mininghttps://conductscience.org/library/genes/2875NCBI Gene
SLC17A526503PubTator's text mininghttps://conductscience.org/library/genes/26503NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36735694

GET https://conductscience.org/api/papers/v1/36735694/references?page=2